Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
166M
-
Number of holders
-
108
-
Total 13F shares, excl. options
-
37.8M
-
Shares change
-
+101K
-
Total reported value, excl. options
-
$570M
-
Value change
-
-$2.75M
-
Put/Call ratio
-
0
-
Number of buys
-
49
-
Number of sells
-
-60
-
Price
-
$15.10
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q4 2018
134 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q4 2018.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 108 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 37.8M shares
of 166M outstanding shares and own 22.81% of the company stock.
Largest 10 shareholders include FMR LLC (5.92M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.09M shares), BlackRock Inc. (3.86M shares), PERCEPTIVE ADVISORS LLC (2.91M shares), WELLINGTON MANAGEMENT GROUP LLP (2.68M shares), STATE STREET CORP (1.54M shares), Point72 Asset Management, L.P. (1.46M shares), Vanguard Group Inc (1.46M shares), RENAISSANCE TECHNOLOGIES LLC (1.32M shares), and VICTORY CAPITAL MANAGEMENT INC (920K shares).
This table shows the top 108 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.